Surgical treatment of bisphosphonate-associated osteonecrosis of the jaw: Technical report and follow up of 21 patients

被引:78
|
作者
Voss, Pit Jacob [1 ]
Oshero, Joel Joshi [1 ]
Kovalova-Mueller, Alice [1 ]
Merino, Egle Alina Veigel [1 ]
Sauerbier, Sebastian [1 ]
Al-Jamali, Jamil [1 ]
Lemound, Juliana [1 ]
Metzger, Marc Christian [1 ]
Schmelzeisen, Rainer [1 ]
机构
[1] Univ Hosp Freiburg, Dept Oral & Maxillofacial Surg, D-79106 Freiburg, Germany
关键词
Bisphosphonate; Necrosis; Jaw; surgical treatment; GUIDED BONE RESECTION; MULTIPLE-MYELOMA; CANCER-PATIENTS; RISK-FACTORS; INTRAVENOUS BISPHOSPHONATES; AVASCULAR NECROSIS; PROSTATE-CANCER; MANAGEMENT; PROTOCOL; TOMOGRAPHY;
D O I
10.1016/j.jcms.2012.01.005
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Introduction: Bisphosphonates are used to reduce skeletal related events in patients with bone consuming diseases such as osteoporosis and bone metastases. However recently there has been an increased awareness of bisphosphonate-associated necrosis of the jaws (BP-ONJ). Many authors propose conservative management in these cases but invariably the problem is not treated successfully allowing the bone defect to worsen. Recently there has been a move to treat this problem surgically. The aim of this retrospective study was to provide a surgical solution for patients suffering from BP-ONJ. Materials and methods: All patients presenting with BP-ONJ were treated with bone debridement of the affected area and multilayer wound closure. The considered variables were: gentler, age, underlying diagnosis, type of bisphosphonate (BP) used, duration of bisphosphonate use, route of administration, location of the osteonecrosis, clinical symptoms, association with dental treatment and surgical outcome. Results: Nineteen cases of a total of 21 demonstrated no recurrence of osteonecrosis during follow up (Mean 16 months - Range 12-24 months). One patient with a bilateral defect showed a dehiscence on one side and a small fistula on the contralateral side 6 weeks post-operatively and required revision surgery. Another patient developed a fistula after 4 weeks that was treated successfully with antibiotics and curettage. No patients had evidence of exposed bone, bland mucosa nor pain at the surgical site. Conclusion: The technique described can be recommended for patients with BP-ONJ if a conservative treatment fails. (C) 2012 European Association for Cranio-Maxillo-Facial Surgery.
引用
收藏
页码:719 / 725
页数:7
相关论文
共 50 条
  • [31] Bisphosphonate-associated osteonecrosis of the jaw: A key role of inflammation?
    Lesclous, Philippe
    Najm, Semaan Abi
    Carrel, Jean-Pierre
    Baroukh, Brigitte
    Lombardi, Tommaso
    Willi, Jean-Pierre
    Rizzoli, Rene
    Saffar, Jean-Louis
    Samson, Jacky
    BONE, 2009, 45 (05) : 843 - 852
  • [32] More on the Resolution of Bisphosphonate-associated Osteonecrosis of the Jaw Reply
    Adachi, Jonathan D.
    Lau, Arthur
    JOURNAL OF RHEUMATOLOGY, 2010, 37 (03) : 676 - 676
  • [33] Bisphosphonate-associated osteonecrosis of the jaw bone: diagnosis and surgical management of a serious complication
    Umbreit, S.
    Reuter, C.
    Gellrich, N. -C.
    Eckardt, A.
    ONKOLOGIE, 2010, 33 : 195 - 195
  • [34] Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer
    Nastro, E.
    Musolino, C.
    Allegra, A.
    Oteri, G.
    Cicciu, M.
    Alonci, A.
    Quartarone, E.
    Alati, C.
    De Ponte, F. S.
    ACTA HAEMATOLOGICA, 2007, 117 (03) : 181 - 187
  • [35] Quality of Life Implications of Bisphosphonate-Associated Osteonecrosis of the Jaw
    Miksad, Rebecca Anne
    Lai, Kuan-Chi
    Dodson, Thomas Benton
    Woo, Sook-Bin
    Treister, Nathaniel Simon
    Akinyemi, Omosalewa
    Bihrle, Marian
    Maytal, Guy
    August, Meredith
    Gazelle, G. Scott
    Swan, J. Shannon
    ONCOLOGIST, 2011, 16 (01): : 121 - 132
  • [36] Bisphosphonate-associated osteonecrosis of the jaw. Diagnostics and therapy
    Voss, P. J.
    Walter, C.
    MKG-CHIRURG, 2013, 6 (02): : 101 - 106
  • [37] Consensus practice guidelines for bisphosphonate-associated osteonecrosis of the jaw
    Philip N Sambrook
    Nature Clinical Practice Rheumatology, 2009, 5 : 6 - 7
  • [38] CLINICAL EXPERIENCE WITH SPIRAMYCIN IN BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW
    Gasparini, G.
    Saponaro, G.
    Di Nardo, F.
    Moro, A.
    Boniello, R.
    Cervelli, D.
    Marianetti, T. M.
    Palazzoni, G.
    Pelo, S.
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2010, 23 (02) : 619 - 626
  • [39] Bisphosphonate-associated osteonecrosis of the jaws: treatment and long-term follow-up in 160 patients
    Vescovi, P.
    Manfredi, M.
    Merigo, E.
    Meleti, M.
    Guidotti, R.
    Sarraj, A.
    Mergoni, G.
    Fornaini, C.
    Bonanini, M.
    Pizzi, S.
    Rocca, J. P.
    Nammour, S.
    DENTAL CADMOS, 2012, 80 (01) : 9 - 21
  • [40] Bisphosphonate-associated Osteonecrosis of Jaw Reoccurrence after Methotrexate Therapy: A Case Report
    Alsalleeh, Fand
    Keippel, Jeffery
    Adams, Lyde
    Bavitz, Bruce
    JOURNAL OF ENDODONTICS, 2014, 40 (09) : 1505 - 1507